Skip to main content

Table 3 Summary of Grade 3 or 4 toxicities

From: Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years

Category

Concomitant (N = 30)

Adjuvant (N = 24)

Hematologic

 Neutropenia

4 (13.3%)

1 (4.2%)

 Lymphocytopenia

15 (50%)

11 (45.8%)

 Thrombocytopenia

1 (3.3%)

0

 Anemia

1 (3.3%)

1 (4.2%)

Hepatic

 Aspartate transaminase

2 (6.7%)

0

 Alanine transaminase

2 (6.7%)

1 (4.2%)

 Pulmonary (pneumonitis)

2 (6.7%)

1 (4.2%)

 Anorexia

4 (13.3%)

1 (4.2%)

 Hyponatremia

3 (10.0%)

0

 Hypokalemia

1 (3.3%)

0

 Skin rash

4 (13.3%)

1 (4.2%)